title: Frovatriptan Vernalis.
abstract: Vanguard (now Vernalis) has developed frovatriptan, a selective 5-HT1B/1D partial agonist licensed from GlaxoSmithKline as a potential treatment for migraine [188478], [194382], [377863].
authors.affiliation: HM Pharma Consultancy, Enenkelstrasse 28/32, A-1160 Wien, Austria. h.mucke@hmpharmacon.com
authors.forename: Hermann A M
authors.initials: HA
authors.lastname: Mucke
mesh_terms: D002227:Carbazoles / Q000737:chemistry / Q000494:pharmacology / Q000627:therapeutic use*; D002986:Clinical Trials as Topic / Q000379:methods / Q000706:statistics & numerical data; D004345:Drug Industry / Q000331:legislation & jurisprudence / Q000379:methods; D008881:Migraine Disorders / Q000188:drug therapy; D017366:Serotonin Receptor Agonists / Q000737:chemistry / Q000494:pharmacology / Q000627:therapeutic use; D014363:Tryptamines
chemical_list: D002227:Carbazoles; D017366:Serotonin Receptor Agonists; D014363:Tryptamines; C108128:frovatriptan